Search Results

treated with trastuzumab, paclitaxel, carboplatin, and gemcitabine, 14 ERBB2 overexpression by IHC, gene amplification in the tumor by FISH, or presence in serum for extracellular ERBB2 domain testing by quantitative enzyme-linked immunosorbent assay was

chemotherapy regimens containing platinum . Gynecol Oncol 2008 ; 108 : 136 – 140 . 28 Homesley HD Filiaci V Markman M . Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group

weekly paclitaxel, 2 single-arm phase II trials evaluated the utility of short-course docetaxel/cyclophosphamide (DCH for 4 cycles) 13 or paclitaxel (weekly for 12 weeks) 14 in combination with trastuzumab for low-risk HER2+ breast cancer. Both trials

randomized phase III ECOG 4599 trial, which demonstrated an OS advantage associated with addition of bevacizumab to carboplatin/paclitaxel. 11 Although results of the PointBreak trial showed that carboplatin/pemetrexed/bevacizumab yielded similar OS compared

paclitaxel in combination be a treatment option for women with metastatic breast cancer. The vote of the NCCN Guidelines Panel on this issue was 15 to 0. The European Medicines Agency, the counterpart of the FDA for the European Union, has adopted a position

. 18. Strauss GA Herndon JE Maddaus MA . Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol

addition of bevacizumab to upfront therapy with carboplatin/paclitaxel or as maintenance therapy at this time. The NCCN panel encourages participation in ongoing clinical trials that are further investigating the role of antiangiogenesis agents in the

preoperative neoadjuvant paclitaxel, ifosfamide, and cisplatin ( TIP ). Stable or responding patients should then undergo surgical resection consolidative surgery ...” For “Preferred radiosensitizing agents and combinations,” the heading was clarified

Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously over 30 minutes and carboplatin intravenously over 1 to 2 hours on day 1. Treatment repeats

with clinical stage T1N1 or T2–3N0–1 disease were eligible, and were randomized to either 41.4 Gy of radiotherapy over 5 weeks with concurrent weekly carboplatin (area under the curve, 2) and paclitaxel (50 mg/m 2 ) followed by surgery, or to surgery